A Deeper Look into Emerging Therapies in the Management of Relapsed/Refractory Multiple Myeloma: What Does Recent Clinical Trial Data Have to Say?

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the treatment and Management of Relapsed/Refractory Multiple Myeloma: What
Managed Care Needs to Know About Emerging Therapies

This is Part 1 of the series focusing on emerging therapies and management of multiple myeloma

This activity is an archive from the webinar held April 28, 2020

This activity is valid from May 1, 2020 to May 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme

Description:
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2020, it is estimated that MM will be responsible for 12,960 new deaths and 32,110 new cases. In recent years, more treatments have become available that have increased survival numbers significantly, though prognosis still remains rather poor, especially in relapsed/refractory (R/R) disease. Fortunately for patients with R/R MM, there are several novel options that have been recently approved or are currently undergoing late stage clinical trials that have shown great promise in their ability to improve clinical outcomes.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical needs in the diagnosis and management of relapsed/refractory multiple myeloma

  • Summarize new evidence on the treatment role, efficacy, and safety of novel agent classes and next-generation therapeutics for patients with relapsed or refractory multiple myeloma

  • Analyze the role of emerging anti-CD38 monoclonal antibodies in the relapsed/refractory multiple myeloma treatment paradigm

  • Explore strategies for sequencing treatment for patients with relapsed/refractory multiple myeloma using novel agents

  • Identify patients with relapsed/refractory multiple myeloma for whom a next-generation therapeutic is an appropriate choice for the next step in the management of their cancer
     

Faculty: Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

Disclosure:

Dr. Orlowski serves on an advisory board for Amgen, Bristol-Myers Squibb, Celgene, EcoR1 Capital, Forma Therapeutics, Genzyme, GSK, Ionis, Janssen Biotech, June Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Sanofi-Aventis, Servier, and Takeda. He has received grants/research support from BioTheryX, CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi Aventis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue